{
  "nctrialId": "HC-1305",
  "title": "A  Open-Label, Placebo-Controlled Multi-Center Study of PUL-502 (bronchodilator) in Patients With Ulcerative Colitis",
  "officialTitle": "A  Open-Label, Placebo-Controlled Multi-Center Study of PUL-502 (bronchodilator) in Patients With Ulcerative Colitis",
  "sponsor": "Montreal Heart Institute",
  "indication": "Ulcerative Colitis",
  "phase": "Phase 1",
  "fileName": "HC-1305.json",
  "fileSize": 164232,
  "date": "2024-10-04",
  "completionDate": "2025-05-07",
  "drugName": "PUL-502 (bronchodilator)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Completed",
  "description": "This is a  open-label, placebo-controlled multi-center study designed to evaluate the efficacy and safety of PUL-502 (bronchodilator) in patients with Ulcerative Colitis. The study will enroll approximately 431 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 23-61 years\n- Confirmed diagnosis of Ulcerative Colitis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}